ENSC
Price
$2.38
Change
+$0.04 (+1.71%)
Updated
Jun 6 closing price
Capitalization
5.51M
SYRE
Price
$16.97
Change
+$0.35 (+2.11%)
Updated
Jun 6 closing price
Capitalization
1.02B
54 days until earnings call
Interact to see
Advertisement

ENSC vs SYRE

Header iconENSC vs SYRE Comparison
Open Charts ENSC vs SYREBanner chart's image
Ensysce Biosciences
Price$2.38
Change+$0.04 (+1.71%)
Volume$80.84K
Capitalization5.51M
Spyre Therapeutics
Price$16.97
Change+$0.35 (+2.11%)
Volume$309.21K
Capitalization1.02B
ENSC vs SYRE Comparison Chart
Loading...
ENSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENSC vs. SYRE commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENSC is a Buy and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ENSC: $2.38 vs. SYRE: $16.97)
Brand notoriety: ENSC and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENSC: 3% vs. SYRE: 50%
Market capitalization -- ENSC: $5.51M vs. SYRE: $1.02B
ENSC [@Biotechnology] is valued at $5.51M. SYRE’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENSC’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ENSC’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ENSC is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENSC’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • ENSC’s TA Score: 5 bullish, 1 bearish.
  • SYRE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ENSC is a better buy in the short-term than SYRE.

Price Growth

ENSC (@Biotechnology) experienced а +7.21% price change this week, while SYRE (@Biotechnology) price change was +11.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

ENSC is expected to report earnings on Mar 10, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.02B) has a higher market cap than ENSC($5.51M). SYRE has higher P/E ratio than ENSC: SYRE (1.72) vs ENSC (0.02). SYRE YTD gains are higher at: -27.105 vs. ENSC (-70.762). ENSC has higher annual earnings (EBITDA): -6.7M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. ENSC (3.5M). SYRE has less debt than ENSC: SYRE (0) vs ENSC (302K). ENSC (0) and SYRE (0) have equivalent revenues.
ENSCSYREENSC / SYRE
Capitalization5.51M1.02B1%
EBITDA-6.7M-214.36M3%
Gain YTD-70.762-27.105261%
P/E Ratio0.021.721%
Revenue00-
Total Cash3.5M565M1%
Total Debt302K0-
FUNDAMENTALS RATINGS
ENSC vs SYRE: Fundamental Ratings
ENSC
SYRE
OUTLOOK RATING
1..100
2914
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
6559
P/E GROWTH RATING
1..100
6381
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENSC's Valuation (28) in the null industry is somewhat better than the same rating for SYRE (75) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew somewhat faster than SYRE’s over the last 12 months.

ENSC's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as ENSC (99) in the null industry. This means that SYRE’s stock grew similarly to ENSC’s over the last 12 months.

SYRE's Price Growth Rating (59) in the Pharmaceuticals Major industry is in the same range as ENSC (65) in the null industry. This means that SYRE’s stock grew similarly to ENSC’s over the last 12 months.

ENSC's P/E Growth Rating (63) in the null industry is in the same range as SYRE (81) in the Pharmaceuticals Major industry. This means that ENSC’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENSCSYRE
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ENSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SUPV12.100.27
+2.28%
Grupo Supervielle SA
TPL1113.2620.20
+1.85%
Texas Pacific Land Corp
VSEC133.641.79
+1.36%
VSE Corp
XYLO4.840.05
+1.04%
Xylo Technologies Ltd
UNB28.68-0.10
-0.36%
Union Bankshares

ENSC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENSC has been loosely correlated with MLLCF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ENSC jumps, then MLLCF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENSC
1D Price
Change %
ENSC100%
+1.71%
MLLCF - ENSC
37%
Loosely correlated
N/A
HNSBF - ENSC
33%
Loosely correlated
N/A
SYRE - ENSC
31%
Poorly correlated
+2.11%
NEUP - ENSC
31%
Poorly correlated
-3.92%
YMAB - ENSC
30%
Poorly correlated
+3.33%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+2.11%
BEAM - SYRE
58%
Loosely correlated
+9.26%
CGON - SYRE
57%
Loosely correlated
+1.05%
IMNM - SYRE
53%
Loosely correlated
+0.11%
APGE - SYRE
53%
Loosely correlated
+8.84%
XNCR - SYRE
53%
Loosely correlated
+5.81%
More